Future Treatments Giving Hopes to ED Patients

Men love being admired in the bedroom. While most women are first drawn to feel is the one for their partner, being mutually attached and emotionally connected to their man, than being loved, men’s prerequisites are based on the sense of physical pleasure, sexual arousal, and orgasm.

t is after the intercourse that the language of the so-called love is more understood by the hombre in the bedroom. However, the bedroom is not at all an inviting place for some men. Instead, it is a place of worries and fears.

Moreover, although it is a topic for which a major part of the masculine population deems not to discuss openly in society or even within the walls of a doctor’s clinic, sexual dysfunction is a reality. One of the causes of this is impotence or erectile dysfunction.

Sexual impotence, erectile dysfunction, or ED, is defined as the disability to develop or maintain erection therefore failure to penetrate the vagina during intercourse.

It has different causes that are generally physiological and health-related or psychological reasons rooted in the emotional state of the patient. Statistical data shows that this is experienced by 10% of the male population. And as the age bracket goes higher, the statistics of cases for this physical disorder go up.

The patient either undergoes disorders in having the desire to perform intercourse, failure to be aroused by the partner, delay, or no orgasm at all and experiencing pain during contact.

Thankfully, with the fast-paced advancement in the different branches of science and technology, men have various choices to address this problem. New impotence treatments are a continuous subject of medical researches and new hopes are given to the masculine population.

The goal of which is to develop treatments that are not painful has fewer side effects, and take effect more quickly.

One of these is the introduction of new erectile dysfunction drugs to the market that could be taken by patients with the prescription of their physician.

The list includes drugs having Alprostadil, Apomorphine, phosphodiesterase inhibitors, and Melanocortin activators as their main active ingredients.

Prostaglandin pharmaceutically known as Alprostadil is a vasodilator that comes with the brand name Caverject, Caverject Impulse, Edex, Muse.

Medicines under this group increase blood flow by widening the blood vessels as the muscles relax.

When there is increased blood flow in the penis, the erection is achieved. One of the classical methods of introducing Alprostadil to the male organ is through injection.

A known example is the practice of injecting Caverject at the Corpus Cavernosum, which is the side of the penis.

Although the method is painless and erection takes place 5 to 10 minutes after the injection, administration of the drug is not advisable for men with hypertension, those with penis deformities, patients with penile implants, or those who are restricted by their physician to undergo sexual activity.

This drug is also found out to cause penile fibrosis also called Peyronie’s disease.

Symptoms observed on male organs with penile fibrosis include inflammation, the presence of scars, lumps, bent penis, or even painful erections. Also, the injection of the drug reportedly causes prolonged erection or priapism that only a small dosage is advised. In this more advanced generation, Topiglan is developed to take away the burden of taking the drug by injection.

It is used as topical cream rubbed at the tip of the male’s organ that stimulates the penis just the same.

Although the application of Topiglan is not all successful to a hundred percent of the tested patient and some claims its ineffectiveness, there are still some studies saying that the majority of those men that underwent the test achieved erection sufficient to perform intercourse.

At present, the use of the drug is not yet approved by the Food and Drugs Administration (FDA).

Past researches and development for the said drug originated at MacroChem Corporation.

Added to the list of new erectile dysfunction drugs to market has the active ingredient Apomorphine.

This chemical, a derivative of Aporphine, targets the brain’s dopamine receptor in the hypothalamus.

The stimulation of this part of the brain serves as the new impotence treatment as it enhances sexual response. As the dopamine receptor is induced, signals are transmitted to the sacral parasympathetic nucleus from the spinal cord followed by the stimulation of the sacral nerves supplying the penis.

Erection is caused by the flow of blood as the penis muscles relax and the arteries dilate.

The drug is marketed with the trade names Ixense — and more currently as Uprima — by Abbott pharmaceutical company.

Uprima is administered sublingually about 20 minutes before sexual activity; it enters the body through the tissues under the tongue. Sublingual administration of drugs is more direct therefore the threat of being degraded before reaching the bloodstream is avoided resulting in a faster effect.

However, the drug is to be taken with precautions because of observed side effects such as headache, dizziness, nausea, vomiting, or even fainting. Uprima is widely available in European markets. Currently, Apomorphine drugs are clinically utilized for the treatment of Parkinson’s disease.

Other drugs used in treating impotence are Sildenafil introduced in 1996 under the most common trade names Viagra and Revatio; Tadalafil approved in 2003 with the trade name Cialis, and Vardenafil legalized in commonly called Levitra or Staxyn.

More current studies focus on the development of Avanafil an enzyme inhibitor. This drug, produced by Vivus Inc., functions as phosphodiesterase inhibitors that specifically target the phosphodiesterase type 5 enzymes (PDE5) found in the different tissues of the human body.

This drug inhibits the degradative action of phosphodiesterase type 5 on cyclic guanosine monophosphate (cGMP) found in the cells of the smooth muscles lining the blood vessels that supply the corpus cavernosum of the penis.

The corpus cavernosum is a sponge-like region in the male sex organ that contains most blood during an erection.

By inhibiting the PDE5 enzymes, there will be a greater concentration of cGMP therefore an increased relaxation of the smooth muscles to allow better blood circulation necessary for penile erection.

A plus on the usage of Avanafil is that it can be taken twice a day when the patient desires to perform a sexual activity more than once.

The bad news however is the results of some clinical trials showing that patients administered with Avanafil tablets experience abnormally low blood pressure or hypotension, flushing or developing visible red marks on some areas of the skin, headache which is the most common, nasal congestion, and heartburn. The effects vary depending on the dosage of the drug administered.

Another hope lies in the development of Melanocortin activators that target the central nervous system. Melanocortins are peptide hormones that activate Melanocortins receptors. Studies using preclinical species show that erectile and sexual functions are influenced because of their effects in the periphery and in the central nervous system.

The drug is formerly known as PT-141 and still in need of further investigations after claims of adverse side effects such as high blood pressure, skin tanning, and spontaneous erection.

New impotence treatment is not limited to the intake of drugs or the use of topical creams. Scientific innovations could make gene therapy a possible way of treating erectile dysfunction. Gene therapy procedures deliver the needed genes into a person’s cells and tissues for the correction of defective or abnormal genes and reproduction of beneficial proteins.

In the case of erectile dysfunction, the treatment aims to work on proteins that are not functioning properly in the penile tissue. If successful, the alteration will make the organ capable of sending signals to the blood vessels that will in turn result in better blood circulation.

Erectile dysfunction is a classical disorder among men. Factors vary from patient to patient and individuals treat the subject from different perspectives. Medical reasons could be heart problems, kidney disease, diabetes, and injuries that damaged the nerves that have control over erections.

A person’s lifestyle such as heavy drinking of alcohol and abuse of other drugs, using tobacco that eventually leads to chronic health disorders is also responsible for some cases of erectile dysfunction.

On the other hand, about 10 to 20 percent of cases are found out to be psychologically related. Some are traced back to traumas experienced by the patient in his childhood. Being burdened by too much stress, anxiety, and depression are also contributing factors.

The person usually develops low self-esteem and indifference as a result of these emotional burdens. In order to identify the roots of the disorder, several tests are done such as physical examination, laboratory tests, psychosocial exams, and investigation on the patients’ history.

To address a person’s problem of impotence, it should not be confined in the bedroom alone. Seeking professional help and opening up to one’s partner helps a lot and makes the quest lighter. Recent researches, although faced with many technological and medical challenges are giving hope to society.

The studies conducted on new impotence treatments and the goals of different companies to introduce new erectile dysfunction drugs to market are promising. With these, erectile dysfunction will not be taboo to society anymore and patients could be able to address the problem without fear. Knowing the facts puts the bedroom worries away.